115 related articles for article (PubMed ID: 38477974)
21. Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer.
Jin L; Garcia J; Chan E; de la Cruz C; Segal E; Merchant M; Kharbanda S; Raisner R; Haverty PM; Modrusan Z; Ly J; Choo E; Kaufman S; Beresini MH; Romero FA; Magnuson S; Gascoigne KE
Cancer Res; 2017 Oct; 77(20):5564-5575. PubMed ID: 28819026
[TBL] [Abstract][Full Text] [Related]
22. Discovery of
Chen Z; Hu B; Rej RK; Wu D; Acharyya RK; Wang M; Xu T; Lu J; Metwally H; Wang Y; McEachern D; Bai L; Gersch CL; Wang M; Zhang W; Li Q; Wen B; Sun D; Rae JM; Wang S
J Med Chem; 2023 Sep; 66(17):12559-12585. PubMed ID: 37647546
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
[TBL] [Abstract][Full Text] [Related]
24. Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer.
Chen L; Han L; Mao S; Xu P; Xu X; Zhao R; Wu Z; Zhong K; Yu G; Wang X
Eur J Med Chem; 2021 Apr; 216():113307. PubMed ID: 33652354
[TBL] [Abstract][Full Text] [Related]
25. Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.
Xiang Q; Wang C; Zhang Y; Xue X; Song M; Zhang C; Li C; Wu C; Li K; Hui X; Zhou Y; Smaill JB; Patterson AV; Wu D; Ding K; Xu Y
Eur J Med Chem; 2018 Mar; 147():238-252. PubMed ID: 29448139
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-4 activates androgen receptor through CBP/p300.
Lee SO; Chun JY; Nadiminty N; Lou W; Feng S; Gao AC
Prostate; 2009 Feb; 69(2):126-32. PubMed ID: 18819102
[TBL] [Abstract][Full Text] [Related]
27. Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression.
Qin C; Hu Y; Zhou B; Fernandez-Salas E; Yang CY; Liu L; McEachern D; Przybranowski S; Wang M; Stuckey J; Meagher J; Bai L; Chen Z; Lin M; Yang J; Ziazadeh DN; Xu F; Hu J; Xiang W; Huang L; Li S; Wen B; Sun D; Wang S
J Med Chem; 2018 Aug; 61(15):6685-6704. PubMed ID: 30019901
[TBL] [Abstract][Full Text] [Related]
28. P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib.
Zhou XR; Li X; Liao LP; Han J; Huang J; Li JC; Tao HR; Fan SJ; Chen ZF; Li Q; Chen SJ; Ding H; Yang YX; Zhou B; Jiang HL; Chen KX; Zhang YY; Huang CX; Luo C
Acta Pharmacol Sin; 2022 Feb; 43(2):457-469. PubMed ID: 33850273
[TBL] [Abstract][Full Text] [Related]
29. Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells.
Pan W; Zhang Z; Kimball H; Qu F; Berlind K; Stopsack KH; Lee GM; Choueiri TK; Kantoff PW
Clin Cancer Res; 2021 Apr; 27(7):2087-2099. PubMed ID: 33495313
[TBL] [Abstract][Full Text] [Related]
30. Targeted degradation of the enhancer lysine acetyltransferases CBP and p300.
Vannam R; Sayilgan J; Ojeda S; Karakyriakou B; Hu E; Kreuzer J; Morris R; Herrera Lopez XI; Rai S; Haas W; Lawrence M; Ott CJ
Cell Chem Biol; 2021 Apr; 28(4):503-514.e12. PubMed ID: 33400925
[TBL] [Abstract][Full Text] [Related]
31. Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong
Yang L; Tu W; Huang L; Miao B; Kaneshige A; Jiang W; Leng L; Wang M; Wen B; Sun D; Wang S
J Med Chem; 2023 Aug; 66(15):10761-10781. PubMed ID: 37523716
[TBL] [Abstract][Full Text] [Related]
32. CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers.
Waddell AR; Huang H; Liao D
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34201346
[TBL] [Abstract][Full Text] [Related]
33. Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors.
Lu W; Xiong H; Chen Y; Wang C; Zhang H; Xu P; Han J; Xiao S; Ding H; Chen Z; Lu T; Wang J; Zhang Y; Yue L; Liu YC; Zhang C; Yang Y; Jiang H; Chen K; Zhou B; Luo C
Bioorg Med Chem; 2018 Nov; 26(20):5397-5407. PubMed ID: 30297119
[TBL] [Abstract][Full Text] [Related]
34. An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells.
Gu ML; Wang YM; Zhou XX; Yao HP; Zheng S; Xiang Z; Ji F
Oncol Rep; 2016 Nov; 36(5):2763-2770. PubMed ID: 27633918
[TBL] [Abstract][Full Text] [Related]
35. Targeting CDCP1 gene transcription coactivated by BRD4 and CBP/p300 in castration-resistant prostate cancer.
Ji D; Shang G; Wei E; Jia Y; Wang C; Zhang Q; Zeng L
Oncogene; 2022 Jun; 41(23):3251-3262. PubMed ID: 35513563
[TBL] [Abstract][Full Text] [Related]
36. Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts.
Fahrenholtz CD; Beltran PJ; Burnstein KL
Mol Cancer Ther; 2013 Apr; 12(4):394-404. PubMed ID: 23348048
[TBL] [Abstract][Full Text] [Related]
37. A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo.
Zhao L; Han X; Lu J; McEachern D; Wang S
Neoplasia; 2020 Oct; 22(10):522-532. PubMed ID: 32928363
[TBL] [Abstract][Full Text] [Related]
38. Discovery of a First-in-Class Degrader for the Lipid Kinase PIKfyve.
Li C; Qiao Y; Jiang X; Liu L; Zheng Y; Qiu Y; Cheng C; Zhou F; Zhou Y; Huang W; Ren X; Wang Y; Wang Z; Chinnaiyan AM; Ding K
J Med Chem; 2023 Sep; 66(17):12432-12445. PubMed ID: 37605297
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and Biological Evaluation of Spirocyclic Chromane Derivatives as a Potential Treatment of Prostate Cancer.
Feng L; Yu S; Wang H; Yang S; Li X; Dai H; Zhao L; Jiang C; Wang Y
Molecules; 2021 May; 26(11):. PubMed ID: 34070610
[TBL] [Abstract][Full Text] [Related]
40. Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression.
Li Y; Yang J; Aguilar A; McEachern D; Przybranowski S; Liu L; Yang CY; Wang M; Han X; Wang S
J Med Chem; 2019 Jan; 62(2):448-466. PubMed ID: 30525597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
